PLYMOUTH
MEETING, Pa., May 23, 2022
/PRNewswire/ -- INOVIO
(NASDAQ:INO), a biotechnology
company focused on developing and commercializing DNA medicines to
help protect people from infectious diseases and treat people with
cancer and HPV-associated diseases, today
announced that Jacqueline Shea, Ph.D.,
President and CEO, and
Jeffrey Skolnik, M.D., SVP
of Clinical Development for Oncology and HPV
Therapeutics, are scheduled to participate in a fireside chat
and 1x1 investor meetings at the Jefferies 2022
Healthcare Conference on Wednesday, June
8th, 2022 at 1:00 PM EDT.
Jefferies 2022 Healthcare Conference
Date:
Wednesday, June 8,
2022
Time: 1:00 PM
EDT
Presentation Format: Fireside Chat
A webcast of the presentation will be available through the
INOVIO Investor Relations Events page at
https://ir.inovio.com/events-and-presentations/default.aspx. The
presentation time is subject to change.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help protect people from
infectious diseases and help treat people with cancer and
HPV-associated diseases. Our DNA medicines are delivered using our
proprietary smart device to produce a robust and tolerable immune
response against targeted pathogens and cancers.
Partners and collaborators include Advaccine, ApolloBio
Corporation, AstraZeneca, The Bill & Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations, Defense Advanced
Research Projects Agency/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense/Department
of Defense, HIV Vaccines Trial Network, International Vaccine
Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium,
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Ology Bioservices,
the Parker Institute for Cancer Immunotherapy, Plumbline Life
Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher
Scientific, University of Pennsylvania,
Walter Reed Army Institute of Research, and The Wistar Institute.
For more information, visit www.inovio.com.
CONTACTS:
Media: Jeff Richardson,
267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076,
ben.matone@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-to-present-at-jefferies-2022-healthcare-conference-301552645.html
SOURCE INOVIO Pharmaceuticals, Inc.